Protease inhibitor resistance in South African children with virologic failure

Pediatric Infectious Disease Journal

Volumn 28, Issue 12, 2009, Pages 1125-1127

  Van Zyl, Gert U ^a   Van Der Merwe, Lize ^b,c   Claassen, Mathilda ^a   Cotton, Mark F ^d   Rabie, Helena ^d   Prozesky, Hans W ^d   Preiser, Wolfgang ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Antiretroviral drug resistance; Pediatric; Protease inhibitor; Ritonavir; Virologic failure

Indexed keywords

LAMIVUDINE; LOPINAVIR; RIFAMPICIN; RITONAVIR; THYMIDINE DERIVATIVE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SOUTH AFRICA;

EID: 74049096099     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181af829d     Document Type: Article

References (17)

1. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63:769-802.
2. Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read. 2001;11:87-98; quiz 107-108.
3. Hurst M, Faulds D. Lopinavir. Drugs. 2000;60:1371-1379; discussion 1380-11371
4. Chadwick EG, Capparelli EV, Yogev R, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS. 2008;22:249-255.
5. Ren Y, Nuttall JJ, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008;47:566-569.
6. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35:275-291.
7. Plantier JC, Dachraoui R, Lemee V, et al. HIV-1 resistance genotyping on dried serum spots. AIDS. 2005;19:391-397.
8. van Zyl GU, Claassen M, Engelbrecht S, et al. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. J Med Virol. 2008;80:942-946.
9. Rudin C, Burri M, Shen Y, et al. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. Pediatr Infect Dis J. 2008;27:431-437.
10. Chadwick EG, Rodman JH, Britto P, et al. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J. 2005;24:793-800.
11. Scherpbier HJ, Bekker V, van Leth F, et al. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics. 2006;117:e528-e536.
12. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233-2244.
13. Kuritzkes DR. Preventing and managing resistance in the clinical setting. J Acquir Immune Defic Syndr. 2003;34(suppl 2):S103-S110.
14. Moyle G. Metabolic issues associated with protease inhibitors. J Acquir Immune Defic Syndr. 2007;45(suppl 1):S19-S26.
15. Macassa E, Delaugerre C, Teglas JP, et al. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children. Pe-diatr Infect Dis J Sep. 2006;25:809-814.
16. Courter JD, Girotto JE, Salazar JC. Tipranavir: a new protease inhibitor for the pediatric population. Expert Rev Anti Infect Ther. 2008;6:797-803
17. FDA notifications. FDA OKs new pediatric dosing for darunavir. AIDS Alert. 2009;24:22-24